RAPID HEMATOLOGIC RESPONSE TO SUTIMLIMAB IN SEVERE COLD AGGLUTININ DISEASE REFRACTORY TO RITUXIMAB IN AN ELDERLY PATIENT (SIE 2026) - Oct 6, 2026 - Abstract #SP009; "The lack of re- sponse to corticosteroids and anti-CD20 therapy, together with the rapid hematologic improvement after complement inhibition, supports the emerging role of Sutimlimab as an effective and fast-acting treatment in refractory CAD. This case underlines the importance of prompt recognition and early access to targeted therapies in life-threatening hemoly- sis."
Clinical • Autoimmune Hemolytic Anemia • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • HP • MYD88
|
|
A. M. Todaro; G. Uccello; O. F. Bianco; U. Consoli
|